To evaluate the efficacy and safety of laser interventions for facial acne scars: a systematic review and Bayesian network meta-analysis
Original Article

To evaluate the efficacy and safety of laser interventions for facial acne scars: a systematic review and Bayesian network meta-analysis

Zixiao Zhao, Tao Wang, Wei Li, Qi Liang, Weihua Chen

Plastic Surgery Laser Center, The Fourth Hospital of Harbin Medical University, Harbin, China

Contributions: (I) Conception and design: T Wang; (II) Administrative support: W Chen; (III) Provision of study materials or patients: W Li; (IV) Collection and assembly of data: Z Zhao; (V) Data analysis and interpretation: Z Zhao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Weihua Chen. Plastic Surgery Laser Center, The Fourth Hospital of Harbin Medical University, Yinhangjie, Harbin 150001, Heilongjiang, China. Email: chenweihua630208@sina.com.

Background: There are numerous laser treatments for acne scars in clinical practice. However, there are no clinical studies comparing all laser methods to provide an evidence-based bias for clinicians to choose the best strategy. Therefore, this systematic review and network meta-analysis was conducted to explore the efficacy of different types of laser treatment on acne scars. This study can provide the most effective treatment for acne scars in clinical practice.

Methods: The databases of PubMed, Embase, Cochrane Library, and Web of Science were searched from their inception to July 2022. The Cochrane risk of bias assessment tool was used to assess the bias of the included original studies. Bayesian network meta-analysis was used to investigate the efficacy of laser treatment strategies in scar improvement, cure rate, and satisfaction.

Results: As shown by the results, the top 3 treatment options for scar improvement were fractional carbon dioxide laser (FCL) + platelet-rich-plasma (PRP) [surface under the cumulative ranking curve (SUCRA): 0.699], 1064Nd (1,064-nm neodymium-doped yttrium aluminum garnet picosecond laser) + 15%VC (Vitamin C; SUCRA: 0.675), and 1064Nd (SUCRA: 0.627). The standard mean difference (SMD) of FCL + PRP was −1.76 (95% CI: −3.49, −0.03), compared with that of FCL. The top 3 treatment options for improving cure rate were Er (Er:YAG laser treatment) + PRP (SUCRA: 0.873), FCL (SUCRA: 0.773), and FCL + 30% salicylic acid (30%SC) (SUCRA: 0.772). The RR of Er + PRP cure rate was 13.86 (95% CI: 1.79, 107.22), compared with non-laser radiofrequency therapy.

Conclusions: The findings suggested that combined therapies should be used to treat acne scars. Er + PRP showed the highest cure rate of acne scar, followed by FCL + 30%SC or FCL monotherapy. FCL combined with PRP could improve acne scarring to the greatest extent, and 1064Nd combined with 15%VC can also exert a good effect. As for satisfaction, FCL monotherapy was the most satisfactory methods for patients, followed by PRP monotherapy. Therefore, Er + PRP and FCL + PRP can be used as the first choice for clinical treatment of acne scars. Additionally, using FCL alone is also an effective and elective treatment method due to its affordable cost and comfort.

Keywords: Laser; acne scar; network meta-analysis

Submitted Nov 16, 2022. Accepted for publication Dec 20, 2022. Published online Dec 01, 2022.

doi: 10.21037/atm-22-5997

Highlight box

Key findings

• This study has identified a meaningful therapeutic approach for acne scars.

What is known and what is new?

• A large number of existing randomized controlled experiments have compared 2–3 acne scar treatments, or a single method for meta-analysis.

• To date, there has been no research on the use of network meta-analysis to compare all laser treatments. This study evaluates the efficacy and safety of laser interventions in the treatment of acne scars, which is an innovative point.

What is the implication, and what should change now?

• This research is more comprehensive, involving more types of lasers, and the results are more instructive. In the future, based on the results of this trial, we should conduct further clinical trials of the most effective treatment to prove the significance of this treatment for acne scars.

Introduction

Acne vulgaris, a chronic inflammatory disorder confined to pilosebaceous units, is characterized by pimples, papules, pustules, and nodules, and is often complicated with scars (1). The onset of acne usually occurs in puberty, affecting approximately 27% of adolescents and 93% of late teens. The face, neck, chest, and upper back are the regions typically affected by acne vulgaris (2). The etiology is complicated, including increased sebum secretion induced by androgens, inflammatory keratinization, colonization of Cutibacterium acnes in the pilosebaceous unit, delayed immune response, diet, and genetic factors (3). Different skin lesions may occur at different stages of the formation and remission of acne vulgaris. Acne scarring is now a common disease leading to impaired facial appearance and significant negative effects on patients’ mental health and daily life (4). Among the population aged 11–30 years, 80% may experience acne at some point, with subsequent scarring affecting about 40% (5). Among the types of scars, the depressed acne scar is relatively serious, which manifests the likeness of an orange peel, ice pick, meteorite crater, and so on (6). Acne scarring is associated with people’s satisfaction with their appearance, low self-esteem, and inferiority complex, which can result in anxiety, depression, and even suicidal thoughts (7).

With the increasing demand for beauty, the healing of acne scars is the focus and challenge of acne treatment. Currently, acne scars are treated with grinding, surgical release, plasma therapy, autologous fibroblasts, platelet-rich-plasma (PRP), and laser therapy, among others. Different treatments for acne scars have different effects and complications (8). At present, laser treatment is the most common method for treating acne scars. The principle of laser treatment is photothermy. Relevant studies have demonstrated that different laser parameters and techniques might have different efficacy on different forms of acne scars (9). The commonly used laser treatments include the 1,064 nm long pulsed neodymium: yttrium-aluminum-garnet (Nd:YAG) laser (1064Nd), 1,550 nm Erbium: glass fractional laser (1550Er), fractional CO2 laser (FCL), 2,940 nm erbium fractional laser (2940FEL), picosecond 755 nm alexandrite laser (755PAL), pulsed dye laser (PDL), and so on. Currently, there are various types of laser treatments for acne scars, but the pros and cons of different laser intervention methods in scar treatment still remain controversial.

The main role of network analysis is to comprehensively evaluate and rank all the interventions in the same body of evidence simultaneously. It can combine both direct and indirect comparisons, which cannot be accomplished by conventional meta-analysis. Therefore, this Bayesian network analysis was conducted to investigate the effect of diversified laser treatment methods on acne scar with the aim of providing a reference for clinical practice. Through searching, we found that there were conflicting results between some studies on the treatment of acne scars. Up to now, there is still a lack of network meta-analysis basis for the selection of laser. Therefore, we carried out this research analysis to explore the optimal method for acne scars. We present the following article in accordance with the PRISMA-NMA reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-5997/rc).

Methods

This systematic review was registered on PROSPERO (ID: CRD42022361585).

Retrieval strategy

Based on the Cochrane Collaboration criteria, the databases of PubMed, Web of Science, Embase, and Cochrane were searched for publicly published randomized controlled trials (RCTs) on laser treatment or combined therapy of laser treatment and other non-laser treatment for acne scars. We also screened relevant meta-analyses published previously. Subject terms and free words were used in the retrieval process, and there was no restriction on region or language. The subject terms mainly included acne, acne vulgaris, and laser, or their synonyms. The detailed retrieval strategy is presented in Table S1.

Inclusion and exclusion criteria

The inclusion criteria were as follows:

  • Population: Patients diagnosed with pathological acne scarring.
  • Intervention: Treatment including laser (monotherapy or combined therapy).
  • Comparison: Different types of lasers, medication, or other non-laser therapeutic strategies.
  • Outcome: ECCA score (échelle d’évaluation clinique des cicatrices d’acné), GBS score (Goodman & Baron quantitative global scarring grading system), cure rate (blinded dermatologists using a quartile grading scale for assessment of clinical improvement of skin smoothness: Grade 1: 0–25% = poor improvement, Grade 2: 26–50% = fair improvement, Grade 3: 51–75% = good improvement, and Grade 4: >75% = excellent improvement), satisfaction (on the last visit, the patients were asked to rate the appearance of the scar, skin texture, and overall satisfaction compared with these factors before treatment on a scale of 1: not satisfied, 2: slightly satisfied, 3: satisfied, and 4: very satisfied).
  • Study design: The included original studies were RCTs.

The exclusion criteria were as follows:

  • Population: Patients with non-pathological acne scars.
  • Intervention: Studies that did not include laser treatments, or the studies used different treatment frequencies/cycles of the same type of laser.
  • Comparison: There was a lack of control groups in the study.
  • Outcome: In the original study, there was a lack of outcome measures evaluating scar improvement, such as cost analyses.
  • Study design: The included original studies were non-RCTs (e.g., retrospective studies, single-arm studies, reviews, etc.).

Interventions

In the included studies, the intervention group mainly used laser therapy, and other therapies combined with non-laser treatment were considered as independent interventions in our meta-analysis to reduce the bias caused by other non-laser therapies.

Literature screening and data extraction

The retrieved literature was imported into Endnote (Clarivate, London, UK). After excluding the duplicated publications, the original studies were screened by titles or abstracts to obtain initially eligible studies. The eligible studies finally included in this research were selected based on the full text. Before data extraction, a standard data extraction spreadsheet was made and the content included title, author, year, comparison, intervention, sample size, intervention protocol, acne scar evaluation form (ECCA and GBS), patients’ satisfaction, response rate, complications, and so on.

The aforementioned literature screening and data extraction were conducted independently by 2 researchers (ZXZ and QL) and cross-checked after completion. If there was any dissent, a third investigator (WHC) was consulted to make a decision.

Quality assessment

Two independent researchers evaluated the risk of bias in the included studies using the Cochrane Collaboration Risk of Bias Tool. Upon the completion of the quality assessment, they cross-checked their results. Any disagreements were solved by a third researcher. The risk of bias assessment by the Cochrane tool involved 7 items in 6 domains: (I) selection bias (random sequence generation, Allocation concealment); (II) performance bias (blinding of participants and personnel); (III) detection bias (Blinding of outcome assessment); (IV) attrition bias (incomplete outcome data); (V) reporting bias (selective reporting); (VI) other bias. Each item was answered as “high risk of bias”, “low risk of bias”, or “unclear”.

Statistical analysis

Network meta-analysis uses the Bayesian random-effects model to compare the effectiveness of various interventions. The Markov chain Monte Carlo method was used for modeling, with four Markov chains running at the same time and the number of annealing set to 20,000. After 50,000 simulation iterations, a model was constructed. The Deviation Information Criterion (DIC) was used to analyze the model fitting and global variable consensus. If there were closed loops, we would use the node-splitting method to analyze the local consensus. Furthermore, interventions were sorted based on surface under the cumulative ranking curve (SUCRA), and a league table was generated to present the difference in the effectiveness between interventions (Table S2). A funnel plot was used to directly reflect the heterogeneity among the studies. Stata 15.0 (Stata Corporation, College Station, TX, USA) was used for data analysis. A P<0.05 indicates statistical significance.

Results

Literature search

After the literature search by subject terms and free words, 120 articles were found in PubMed, 528 in Embase, 368 in Cochrane, and 491 in Web of Science. After excluding 523 duplicated publications, 984 articles remained. Afterwards, 155 articles were screened by reading of titles and abstracts. Articles were excluded if the full text was not available or the research subjects did not meet the inclusion criteria. A total of 72 articles were finally included (Figure 1).

Figure 1 The flowchart of literature screening.

The basic characteristics of the included studies

After downloading the full text for screening, a table of basic characteristics was created to extract the basic characteristics of the included studies (Table 1). Among the 72 included articles, 18 were from Egypt, 13 from China, 11 from Korea, 8 from Thailand, 5 from the USA, 6 from India, 2 from Iraq, 1 from Indonesia, 1 from the UK, 2 from Turkey, 1 from Belgium, 1 from Brazil and 3 from Iran. The sample size was between 5 and 350 cases, and the publication time was from 2004 to 2022.

Table 1

Basic information of the included literatures

No. Author Year Study design Country Intervention Number of cases [faces] Total number of samples [faces] Gender (male/female) Age, years Course of the disease Course of treatment Follow-up time Outcome indicator
1 Zhang YJ (6) 2022 Randomized, split-face study China 30% supramolecular salicylic acid + ultra-pulsed CO2 fractional laser; ultra-pulsed CO2 fractional laser 20; 20 20 [40] – – – – 3 months ECCA
2 Wang Y (10) 2022 Randomized China Fractional CO2 laser; fractional CO2 laser + PRP + Yifu 350; 350 700 66 M 84 F; 64 M 86 F 15–31; 16–32 1–2 years – – Clinical effect, ECCA, DLQI, VSS
3 Sabry HH (11) 2022 Split-face comparative double-blinded Egypt Long-pulsed Laser Nd:YAG 1,064 nm; fractional CO2 laser 20; 20 20 [40] – At least 18 – – – –
4 Lu K (12) 2022 Prospective, simultaneous spilt‑face China Fractional non-ablative 1,927 nm thulium laser (FTL) 1,927 nm; fractional ablative 2,940 nm Er:YAG laser (FEL) 2,940 nm 27; 27 27 [54] 16 M 11 F; 16 M 11 F 26; 26 – – – GBS, patients’ satisfaction
5 Gawdat HI (13) 2022 Split-face randomized Egypt PRP ‘fluid + fractional CO2 laser; PRP ‘gel + fractional CO2 laser 27; 27 27 [54] – – – – – Clinical assessment scores, ECCA
6 Emam AAM (14) 2022 Split-face comparative Egypt 2,940 nm fractional Er: YAG laser 21; 21 21 [42] – – – 16 weeks 3 months GBS
7 Allam N (15) 2022 Randomized clinical Egypt Monopolar radiofrequency; pulsed dye laser 15; 15 30 – – – 1 session (8 minutes for each cheek) per month of MFR for 4 months. 1 session (5 minutes for each cheek) per month of PDL for 4 months – ECCA, FASQoL (this is a 10-item assessment tool with 3 do-mains for evaluating the emotional, social, and work/school-related effect of scars), SCARS [self-assessment questionnaire (using a scale of 0–10)]
8 Sirithanabadeekul P (16) 2021 Randomized split-face comparative Thailand, Fractional picosecond 1,064-nm laser; fractional CO2 laser 25; 25 25 [50] – – – 3 months – Skin imaging, physician improvement scores
9 Shi Y (8) 2021 Randomized, split-face, double-blind China Fractionated frequency-doubled 1,064/532 nm picosecond Nd:YAG laser; non-ablative fractional 1,540 nm Er: glass laser 22; 22 22 [44] – – – 4 monthly treatments 1 month ECCA, PRIMOS (a 3D imaging system), two physicians (with 15 and 30 years of work experience, respectively), who were blinded to the grouping, evaluated the treatment efficacy
10 Rajput CD (17) 2021 Prospective, nonrandomized, open-label India Fractional CO2 laser; fractional microneedling radio frequency 25; 25 50 – – – 4 sessions were given for both the groups at an interval of 2 months – GBS
11 Pratiwi I (18) 2021 Double-blind, randomized controlled Indonesia Long-pulsed Laser Nd:YAG 1,064 nm + Vitamin C; long-pulsed Laser Nd:YAG 1,064 nm 9; 9 18 – – – – – GBS
12 Lan T (19) 2021 Pilot randomized Split-face clinical China Fractional micro-plasma radiofrequency; fractional microneedle 60; 60 60 [120] 39 M/21 F 17–30 (average 22.87 ±2.51) 3 applications of treatment at 2-month intervals 1, 3, 6 months after the final treatment ECCA, dermatologists evaluation, patient self-evaluation, DLQI scores, adverse effects
13 Kimwattananukul K (20) 2021 Double-blind, placebo-controlled Thailand 0.5% timolol maleate; normal saline; fractional CO2 laser 25; 25 25 [50] 12 M/13 F 18–50, mean 31.4 At least 3 months – – Skin hydration, crusting score
14 Feng H (21) 2021 Randomized, evaluator-blinded, left-to-right split-face China Intense pulsed light; fractional 1,064 nm Nd:YAG picosecond laser + intense pulsed light 15; 15 15 [30] – 18–60 – – five sessions of treatment at weeks 0, 4, 8, 12, 16 and were followed up at week 28 ECCA, DLQI, TEWL, MI
15 El-Hawary EE (22) 2021 Comparative clinico-immuno-histopathological Egypt PRP; ablative fractional CO2 laser; PRP + FCO2 20; 20; 20 60 [22M/38F] 40% M/60% F; 40% M/60% F; 30% M/70% F Aged 20–35 (mean 24.60±3.20) – Each group received 3 sessions at monthly intervals – Clinical, histopathological
16 Cheng X (23) 2021 Randomized split-face China 10,600 nm ablative fractional laser; 1,565 nm nonablative fractional laser 19; 19 19 [38] – – – – – Erythema, crusting durations, and degree of pain
17 Chen L (24) 2021 China 2,940 Er:YAG laser treatment in the microlaser peeling; fractional ablative laser; combined modes 30; 30; 30 90 – – – – – ECCA, self-evaluation of treatment satisfaction by the patient
18 Al-Dhalimi MA (25) 2021 Split-face clinical comparative Iraq 2,940 nm fractional Er: YAG laser; long pulsed Nd:YAG 1,064 nm laser 20; 20 20 [40] – – – 3 sessions at a 3-week interval – Sharquie scores, digital photographic assessment, patient’s satisfaction
19 Abdel-Maguid EM (26) 2021 Split-face clinical Egypt Fractional CO2 laser + topical SC-CM or fractional CO2 laser + saline; fractional CO2 laser + topical PRP or SC-CM 17 [34]; 16 [32] 33 [66] – – – 3 monthly sessions – ECCA, 2 blinded dermatologists
20 Sallam MAE (27) 2021 Split face comparative Egypt Microneedling with PRP; fractional CO2 laser with PRP 20; 20 20 [40] – – – – – GBS
21 Wen X (28) 2020 Randomized split face, investigator-blinded China 755 nm picosecond alexandrite laser fitted with DLA; within-patient control 16; 16 16 [32] – – – three treatments at 1-month intervals – ECCA, CEAS
22 Pooja T (29) 2020 Randomized India Fractional CO2 laser; microneedling; PRP 20; 20; 20 60 – Age range of 16–45 – Monthly intervals for 4 sessions. – GBS
23 Mahamoud WA (4) 2020 Split face Egypt Fractional CO2 laser + PRP; fractional carbon dioxide laser + noncross-linked hyaluronic acid 30; 30 30 [60] 14 M/16 F – – 3 sessions of full-face fractional CO2 laser re- surfacing – GBS grading system, 2 blinded investigators
24 Lakkireddygari S (30) 2020 Comparitive India Fractional CO2 laser; fractional CO2 laser + autologous platelet rich plasma 40; 40 80 – – – 6 sessions at 1 month intervals – Scar score
25 Kwon HH (31) 2020 Prospective, double-blind, randomized, split-face Korea Fractional CO2 laser + human adipose tissue stem cell-derived exosomes; fractional CO2 laser + control gel 25; 25 25 [50] – – – – – –
26 Kwon HH (32) 2020 Prospective, randomized, split-face, controlled Korea 1,064-nm neodymium-doped yttrium aluminum garnet picosecond laser using a diffractive optical element; nonablative 1,550-nm erbium-glass laser 25; 25 25 [50] 11 M/14 F Aged 19–37 – 3-week intervals 8 weeks ECCA, IGA, patients’ reports at the final visit
27 Abdel Kareem IM (33) 2020 Comparative split face Egypt Fractional CO2 laser; fractional CO2 laser + CO2gas – – – 17–42 – – – Follow-up photographs, patient satisfaction
28 Kaçar N (34) 2020 Prospective, split-face, single-blinded, controlled clinical Turkey Fractional CO2 lasers; F CO2vs. FRF + fractional radiofrequency 27; 27 27 [54] – – – – – ECCA, patient satisfaction
29 Chopra A (35) 2020 Comparative India Microneedling; fractional CO2 30; 30 60 – – – Every 4 weeks for a period of 24 weeks – Per quantitative global acne scarring classification
30 Chen CJ (36) 2020 Split face, randomized controlled China Intense pulsed light; pulsed dye laser 21; 21 21 [42] – – – 2 weeks interval for 4 treatment sessions – VISIA data, acne lesion counts, complications, and skin biopsies
31 Chayavichitsilp P (37) 2020 Randomized, single-blinded, intrapatient, left- to-right comparative Thailand Fractional Nd:YAG 1,064-nm picosecond laser; fractional 1,550-nm erbium fiber laser 30; 30 30 [60] 16 M/14 F Age ≥18 – 4 times at 4-week intervals – ECCA
32 Arsiwala NZ (38) 2020 Hospital-based prospective, double blinded, randomized, and comparative India PRP + fractional CO2 laser; fractional CO2 laser 17; 16 33 21 M/11 F 24.36±4.37 – – Follow-up for next laser session every 4 weeks up to 12 weeks GBS qualitative grading
33 An MK (39) 2020 Randomized controlled split-face Korea Topical poly-lactic acid; microneedle fractional radiofrequency 36; 36 36 [72] – – – – – Acne scar assessment score assessment of patient satisfaction
34 Al-Sultany HA (40) 2020 Comparative Iraq Fractional CO2 laser; MFR 21; 21 42 15 M/6 F 20–48, average 36 – Once monthly for 4 months – GBS scale
35 El-Taieb MA (41) 2019 Randomized clinical Egypt Fractional erbium-YAG laser; PRP; fractional erbium-YAG laser + PRP 25; 25; 25 75 – – – – – GBS, system clinical, assessment clinical improvement, clinical satisfaction
36 Al Taweel AI (42) 2019 Comparative Egypt Fractional CO2 laser + PRP; carboxytherapy + PRP 20; 20 40 – – – – – Acne scars, patients’ satisfaction
37 Abou Eitta RS (43) 2019 Single-center, split-face, prospective clinical Egypt Fractional CO2 laser; autologous adipose-derived stem cells 10; 10 10 [20] – – – – 3 months GBS, scar area percentage, skin function
38 Elsaie ML (44) 2018 – Egypt Ablative 10,600 nm CO2 lasers; nonablative 1,540 nm erbium doped glass laser 29; 29 58 39 M/19 F Aged 18–45 – 4 treatment sessions with a 3-week-free interval – 2 blinded dermatologists, subjective assessment
39 Dierickx C (45) 2018 – Belgium Picosecond 755 nm alexandrite laser 7; 7 7 [14] – – – – – 6-point grading score
40 Abdel Aal AM (46) 2018 Single-blinded, comparative split-face Egypt Fractional CO2 laser; PRP + fractional CO2 laser 30; 30 30 [60] – – – – 3 days, 7 days, 1 month, and 3 months after sessions GBS
41 Saluja SS (47) 2017 Randomized split-face controlled America 1,550 nm non-ablative fractional laser; oral isotretinoin 10; 10 10 [20] – – – – Blinded dermatologist
42 Osman MA (48) 2017 Randomized fplit-face clinical Egypt Fractional erbium-doped Yttrium aluminum garnet laser; microneedling 30; 30 30 [60] 20 M/10 F Aged 21–41 – – 3 months Patient satisfaction, clinical assessment
43 Min S (49) 2017 Prospective, single-blind, and comparative (randomized split-face) clinical Korea Er: YAG laser; bipolar radiofrequency combined with infrared diode laser 24; 24 24 [48] – – – – – ECCA, 5-point Investigator’s Global Assessment
44 Kwon HH (50) 2017 Prospective, randomized split-face Korea Non-ablative 1,550-nm Erbium-glass laser + microneedling radiofrequency; microneedling radiofrequency 28; 28 28 [56] 15 M/13 F – – 16-week – IGA, ECCA
45 Khamthara J (51) 2017 Randomized, split-face, evaluator-blinded, placebo-controlled, comparative Thailand Silicone gel; placebo; ablative Er:YAG laser 19; 19 19 [38] – – – – – Subject’s evaluation, physicians’ global evaluation
46 Faghihi G (52) 2016 Split-face randomized clinical Iran Ablative CO2 resurfacing laser + PRP; ablative carbon dioxide resurfacing laser 16; 16 16 [32] 12 M/4 F – – – – –
47 Cachafeiro T (53) 2016 Randomized clinical Brazil Non-ablative fractional erbium laser 1,340 nm; microneedling 22; 20 42 – – – – – Generalized estimating equation, Mann-Whitney test
48 Anupama YG (54) 2016 – India Subcision followed by CO2 laser; CO2 laser alone 25; 25 50 – – – 4 sessions at 4-week interval – –
49 Faghihi G (55) 2015 Randomized split-face clinical Iran Fractional CO2 laser; punch elevation combined with fractional carbon dioxide laser 42; 42 42 [84] – – – – – 2 dermatologists blinded to treatment
50 Chae WS (56) 2015 Comparative Korea 1,550 nm Er:Glass fractional laser; fractional radiofrequency microneedle 20; 20 40 – – – – – ECCA
51 Yuan XH (57) 2014 Comparison China Fractional CO2 laser (20 mJ, density 10% and the other half with 20 mJ, density 20%); Fractional CO2 laser (10 mJ, density 10% and the other half with 20 mJ, density 10%) 10; 10 20 [40] 10 M/10 F Aged 22–31 – – – 2 blinded dermatologists self-assessment
52 Rongsaard N (58) 2014 Randomized split-face clinical Thailand Fractional erbium-doped glass 1,550-nm; fractional bipolar RF 20; 20 20 [40] – Aged 18–55 – – – 3 blinded dermatologists, patients evaluated clinical improvement texture scores
53 Leheta TM (59) 2014 Randomized controlled Egypt PCI + TCA 20%; 1,540 nm non-ablative fractional laser; 1,540 nm fractional laser + PCI + TCA 20% 13; 13; 13 39 – – – – – Scar severity scores
54 Ahmed R (60) 2014 – Egypt CO2 laser without needling; CO2 laser with needling 30; 30 30 [60] – – – 4 sessions at 3-week interval 3 months GBS, acne scar severity index, qualitative scarring grading system
55 Zhang Z (61) 2013 Randomized split-face clinical China Fractional microplasma radio frequency technology; CO2 fractional laser 33; 33 33 [66] – – – – – ECCA, patient satisfaction
56 Mohammed G (62) 2013 Randomized clinical Egypt CO2 laser with needling applied; CO2 laser without needling applied 30; 30 60 – – – Five times at 2- to 3-week intervals – Acne scar severity index, GBS, patient satisfaction evaluation score
57 Manuskiatti W (63) 2013 – Thailand fractional Er:YAG; CO2 lasers 24; 24 24 [48] – 22–51 – 2 treatments with a 2-month interval 1, 3, and 6 months after the final treatment Two blinded medical assessors, Patient Self-Assessment, Scar Volume Assessment
58 Lee JW (64) 2011 Simultaneous split-face Korea Ablative CO2 fractional + PRP; ablative CO2 fractional 14; 14 14 [28] 4 M/14 F 28.1 (range, 21–38) – – – 2 different blinded dermatologists
59 Asilian A (65) 2011 – Iran Q-Switched 1,064-nm Nd:YAG laser; fractional CO2 laser 32; 32 64 – – – – – Patients satisfaction, physicians’ assessment, two blinded dermatologists
60 Alexis A (66) 2011 Prospective, split-face, randomized, controlled America 1,550 nm erbium-doped fractionated laser [40 mJ and treatment level 4 (11% surface area coverage)]; 1,550 nm erbium-doped fractionated laser [40 mJ and treatment level 7 (20% surface area coverage)] 18; 18 18 [36] – – – – – QGSGSS, blinded investigator global VAS, Skindex-16
61 Mahmoud BH (67) 2010 Prospective, single-blind, randomized America 1,550-nm fractional laser (10 mJ); 1,550-nm fractional laser (40 mJ) 15 3 M/12 F – – – – Blinded evaluators
62 Hedelund L (68) 2010 Randomized controlled the UK 1,540-nm nonablative fractional laser 5; 5 10 – 18–60 – – – Scar texture, skin colour, patients significance
63 Cho SB (69) 2010 Randomized split-face Korea 1,550-nm erbium-doped FPS; 10,600-nm CO2 FS 8; 8 8 [16] 8 M Mean 21.3, range 20–23 – – 3 months Two blinded dermatologists
64 Wanitphakdeedecha R (70) 2009 – Thailand VSP Er:YAG laser (300 micros/1,500 micros) 12; 12 24 – – – – 1, 2, and 4 months Skin smoothness, scar volume
65 Min SU (71) 2009 Randomized split-face clinical Korea Long-pulse Nd:YAG laser; 585/1,064-nm laser + long-pulse Nd:YAG laser 19; 19 19 [38] ECCA, patient satisfaction
66 Lee DH (72) 2009 Randomized split-face clinical Korea PDL; 1,064-nm long-pulsed Nd:YAG laser 18; 18 18 [36] ECCA
67 Kim HJ (73) 2009 Simultaneous split-face Korea 1,550 nm erbium: glass fractional laser; chemical reconstruction of skin scars 20; 20 20 [40] Objective and subjective improvement
68 Yaghmai D (74) 2005 – America 1,064 nm Nd:YAG laser; 1,320 nm Nd:YAG laser 6; 6 12 Evaluated by photographic and profilometric methods
69 Tanzi EL (75) 2004 Prospective clinical and histologic America Long-pulsed 1,320-nm Nd:YAG; 1,450-nm diode lasers 20; 20 20 [40] Clinical improvement, patient satisfaction scores

PRP, platelet-rich plasma; Nd:YAG, neodymium-doped yttrium aluminium garnet; FTL, fractional non-ablative; Er:YAG, Erbium:Yttrium-Aluminum-Garnet; MFR, microneedling fractional radiofrequency; PCI, percutaneous collagen induction; TCA, trichloroacetic acid; FPS, fractional photothermolysis systems; FS, fractional laser system; VSP, variable square pulse; PDL, pulsed dye laser; ECCA, échelle d’évaluation clinique des cicatrices d’acné; DLQI, dermatology quality of life index; VSS, Vancouver scar scale; GBS, Goodman and Baron; CEAS, Clinician Erythema Assessment Scale; IGA, Investigator’s Global Assessment; TEWL, trans-epidermal water loss; MI, melanin index; RF, radiofrequency; SCCM, stem cell-conditioned medium; QGSGSS, Quantitative Global Scarring Grading System Score; VAS, visual analog scale.

Quality evaluation

The included studies were all RCTs. There were 3 methods of random allocation among the included studies: the table of random digits was used in 6 studies, computer software in 8 studies, and sequence generation in 1 study. The remaining studies did not report the method of random allocation. Allocation concealment by using closed envelopes was reported in 4 articles. A total of 25 studies used blinding to reduce performance bias, among which 7 studies used double-blinding and 18 used single-blinding. There were 22 studies that used blinding in outcomes measurement to reduce measurement bias, among which 3 studies used single-blinding, 16 used double-blinding, and 3 used triple-blinding. The number of drop-out patients ranges from one to nine (Figure 2).

Figure 2 Summary of risk of bias assessment.

Meta-analysis results

Evaluation of scar improvement

The ECCA and GBS methods were used to evaluate the improvement of acne scars. The standard mean difference (SMD) was used in the meta-analysis.

Some 14 interventions were involved in the 18 included studies (1,6,8,10,12,14,15,17,18,26,32,38,40,43,49,50,56,61), among which 6 were combined therapies [1064Nd + 15%VC, Er + RF, 30%SC + FCL, FCL + PRP, FCL + HA, FCL + SC-CM (stem cell-conditioned medium)] and 8 were monotherapies (1064Nd, Er, FCL, MTS, ASC, RF, 1927FTL, PDL). The network demonstrated the direct or indirect relationship between the 14 interventions. A closed loop was formed by FCL, FCL + PRP, and FCL + SC-CM interventions. The number of studies on FCL ranked the first, followed by the number of studies on Er. The number of studies on comparisons between FCL and FCL + PRP was the highest (Figure 3) (laser abbreviations involved in the text are shown in Table 2).

Figure 3 The network of evaluating the effects of different interventions on improving acne scars.

Table 2

Laser abbreviations

Treat Intervention Abbreviation
Treat 1 Fractional carbon dioxide laser FCL
Treat 2 30% supramolecular salicylic acid 30%SC
Treat 3 Monopolar radiofrequency RF
Treat 4 Pulsed dye laser PDL
Treat 5 Er:YAG laser treatment Er
Treat 6 Fractional radiofrequency microneedle MTS
Treat 7 1,064-nm neodymium-doped yttrium aluminum garnet picosecond laser 1064Nd
Treat 8 Fractional non-ablative 1,927 nm thulium laser 1927FTL
Treat 9 Autologous adipose-derived stem cells ASC
Treat 10 Stem cell-conditioned medium SC-CM
Treat 11 Platelet-rich plasma PRP
Treat 12 Non-cross-linked hyaluronic acid HA
Treat 13 Fractional microneedle FM
Treat 14 carboxytherapy CO2gas

According to the SUCRA value, different laser treatments were ranked as follows: FCL + PRP (0.699) > 1064Nd + 15%VC (0.675) > 1064Nd (0.627) > 1927FTL (0.582) > FCL + HA (0.58) > Er (0.576) > Er + RF (0.541) > PDL (0.514) > MTS (0.510) > FCL + 30%SC (0.444) > ASC (0.364) > FCL + SC-CM (0.312) > FCL (0.299) > RF (0.277). It was shown that FCL + PRP (0.699) ranked the first, followed by 1064Nd + 15%VC (0.675). All the interventions were compared with the others using a league table. As shown by Table S2, the improvement of the acne scars was the continuous variable. The confidence intervals (CIs) of most pairwise comparisons included 0, indicating that there was no significance in most pairwise comparisons of the intervention. Compared with FCL, scars were significantly improved after FCL + PRP treatment (SMD: −1.76; 95% CI: −3.49 to −0.03). The ranking of improvement of the acne scars is shown in Table S2. The funnel plot was symmetric, indicating that the publication bias was not significant (Figure 4 and Figure 5).

Figure 4 The SUCRA of evaluating the effects of different interventions on improving acne scars. SUCRA, surface under the cumulative ranking curve.
Figure 5 The funnel plot of evaluating the effects of different interventions on improving acne scars. A: 1064Nd; B: 1064Nd + 15%VC; C: 1927FTL; D: 30%SC + FCL; E: ASC; F: Er; G: Er + RF H: FCL; I: FCL + HA; J: FCL + PRP; K: FCL + SC-CM; L: MTS; M: PDL; N: RF.

Cure rate

A total of 13 studies (10,12,24,33,41-44,46,48,50,52,56) reported a cure rate. A total of 12 types of interventions were included, of which 7 were combined therapy (CO2gas + PRP, FCL + CO2gas, Er + FCL, FCL + 30%SC, FCL + PRP, FCL + yifu, Er + PRP) and 5 were monotherapies (FCL, RF, MTS, PRP, ER). A total of 5 closed loops were formed. The sample size of the studies on FCL was the largest, followed by the studies on Er. There were more studies reporting the comparison of FCL and FCL + PR and comparison of FCL and ER (Figure 6).

Figure 6 The network on the cure rate of different interventions.

A ranking table demonstrated the ranking of the cure rates of acne scar by different interventions: Er + PRP (0.873) > FCL (0.773) > FCL + 30%SC (0.772) > FCL + yifu (0.732) > FCL + CO2gas (0.675) > FCL + PRP (0.641) > Er + FCL (0.449) > CO2gas + PRP (0.446) > MTS (0.261) > Er (0.217) > RF (0.106) > PRP (0.057), among which Er + PRP (0.873) ranked the first (Figure 7).

Figure 7 The SUCRA of evaluating the cure rate of different interventions. SUCRA, surface under the cumulative ranking curve.

Table S3 presented that the CI in the pairwise comparison of some interventions included 1. Since the cure rates was a categorical variable, this result indicated that the comparison was non-significant. Compared with FCL, the cure rate of FCL + PRP was increased (SMD: 1.64, 95% CI: 1.17 to 2.28). Compared with PRP, the cure rate of FCL + 30%SC was increased (SMD: 23.97, 95% CI: 1.59 to 361.84). Compared with PRP, the cure rate of Er + PRP was increased (SMD: 21.91, 95% CI: 4.02 to 119.41). Other significant comparisons included FCL vs. RF, FCL vs. PRP, FCL + yifu vs. FCL, FCL + yifu vs. RF, FCL + yifu vs. PRP, FCL + yifu vs. MTS, FCL + yifu vs. CO2gas + PRP, FCL + PRP vs. FCL, FCL + PRP vs. RF, FCL + PRP vs. PRP, FCL + 30%SC vs. RF, FCL + 30%SC vs. PRP, Er + PRP vs. RF, Er + PRP vs. PRP, Er + FCL vs. FCL, Er + FCL vs. RF, Er + FCL vs. PRP, Er + FCL vs. MTS, Er + FCL vs. Er, Er + FCL vs. CO2gas + PRP, Er vs. RF, and Er vs. PRP. The ranking of the cure rates of acne scar is depicted in Table S3. The risk of bias of the studies was assessed, revealing that most studies were evenly distributed on both sides of the effect size, indicating that the publication bias was non-significant (Figure 8).

Figure 8 The funnel plot of evaluating the cure rate of different interventions. A: CO2gas + PRP; B: Er; C: Er + FCL; D: Er + PRP; E: FCL; F: FCL + 30%SC; G: FCL + CO2gas; H: FCL + PRP; I: FCL + yifu; J: MTS; K: PRP; L: RF.

Satisfaction

There were 8 studies (15,16,24,41,42,44,46,52) that reported satisfaction. A total of 8 types of interventions were included, of which 3 were combined therapy (Er + PRP, FCL + PRP, CO2gas + PRP) and 5 were monotherapies (FCL, 1064Nd, Er, PRP, RF). A total of 3 closed loops were formed. The sample size of the studies on FCL was the largest, followed by the studies on FCL + PRP. There were more studies reporting the comparison of FCL and FCL + PRP (Figure 9).

Figure 9 The network of evaluating patients’ satisfaction after treatment for acne scars.

The interventions were ranked according to SUCRA values: FCL (77.2) > PRP (0.649) > CO2gas + PRP (0.530) > Er + PRP (0.524) > FCL + PRP (0.423) > 1064Nd (0.393) > Er (0.364) > RF (0.346) (Figure 10).

Figure 10 The SUCRA of evaluating patients’ satisfaction after receiving different interventions for acne scars. SUCRA, surface under the cumulative ranking curve.

The pairwise forest plot and Table S4 showed the comparison between any 2 interventions (Figure 5). The CI of all the comparisons included 1. Since satisfaction was a categorical variable, the results indicated that all the comparisons were non-significant.

The funnel plot presented that the distribution of the studies was mostly symmetrical, indicating a non-significant publication bias (Figure 11).

Figure 11 The funnel plot of evaluating patients’ satisfaction after receiving different interventions for acne scars. A: 1064Nd; B: CO2gas + PRP; C: Er; D: Er + PRP; E: FCL; F: FCL + PRP.

For the safety of each laser intervention method, there will be a certain degree of complications, such as erythema, edema, pigmentation, exudation, purpura, pain, and so on. These complications are diverse, and the complications of different intervention methods are also different, which can not be uniformly evaluated.

Discussion

There are various options for treating acne scars. Laser treatment, a non-invasive method, has gradually become a mainstream choice with the maturity of optoelectronic technology and the invention of various laser devices. Therefore, we conducted this network meta-analysis to directly or indirectly compare the effects of multiple interventions on acne scarring. A focus of this study was to determine the most effective methods of treating acne scars. The top 3 treatments were Er + PRP, FCL monotherapy, and FCL + 30%SC. The most effective method was Er laser + PRP, which might be attributed to the 2 modes of Er (short-pulsed and dual-mode Er:YAG) (76). Furthermore, the commonly used wavelength of Er laser is 2,940 nm, and its peak absorption coefficient of Er for water is higher than that of FCL (48). A previous meta-analysis compared FCL and Er laser and found that there was no significant difference in efficacy between the 2 devices and both were effective in the treatment of acne scarring (77). This is also the reason why acne scars can be effectively treated. PRP has a synergistic effect with Er to maximize the cure rate. Currently, there is a lack of meta analyses comparing Er with other laser treatments. A 30% salicylic acid concentration can increase the efficacy of FCL, which may reduce the repeat times of laser treatments. This indicates that salicylic acid can achieve better therapeutic effects with fewer laser treatments. The economic burden can be reduced for patients without increasing pain and adverse reactions (6). However, this study found that there was no difference in the cure rate between FCL and FCL + 30%SC, indicating that 30%SC might only be advantageous in increasing the efficiency of laser for 1 time. The cure rate of FCL could not be increased generally. This result should be validated by further research with extended follow-up time and larger sample size. As for the improvement of acne scarring assessed by ECCA and GBS scales, the top 3 treatments were FCL + PRP, 1064Nd + 15%VC, and 1064Nd monotherapy. There were RCTs (22) and meta-analyses (78) showing that FCL + PRP was better than FCL monotherapy in treating acne scars. There were also meta-analyses comparing FCL with other treatments (9). FCL + PRP has gradually become one of the most important treatments for acne scars. However, there is a lack of meta analyses comparing FCL + PRP with other treatments. Therefore, there is no evidence on the relationship between FCL + PRP and other treatments to support the results in our study. There were RCTs demonstrating that 1064Nd had the same efficacy as FCL in the treatment of atrophic acne scars (16). Although they were both combined therapies, this study showed that FCL + PRP had better effects on the improvement of acne scars compared with 1064Nd + 15%VC. In the treatment for atrophic acne scars, long-pulse Nd:YAG 1064 nm laser + 15% vitamin C solution (ascorbic acid) was more effective in reducing GBS scores compared with long-pulse Nd:YAG 1064 nm laser monotherapy, which was consistent with the results in our study. However, no study had investigated whether there is difference in the efficacy between the combined therapy and 1064Nd monotherapy (18). This requires extensive long-term research for more comprehensive results. According to our analysis, in terms of patient satisfaction, the top 3 treatments were FCL, PRP, and CO2gas + PRP. A previous meta-analysis compared FCL with other laser treatments and the results showed that the efficiency of FCL was much higher than that of other treatments (9) in treating acne scars. The improvement of appearance was a key reason for increased patient satisfaction. The cure rate of FCL was less than that of FCL + PRP (26). However, intradermal injection into the inflammatory skin (due to prior treatment with FCL) could lead to worsening pain (22), which might greatly influence patient satisfaction. Patients may ignore the treatment effect due to intense pain and feel more satisfied with FCL monotherapy. Efforts are still required to balance the treatment effect and adverse reactions in clinical practice. Although PRP is a non-laser method and its efficacy is inferior to that of laser treatment or combination therapy, it has the advantages of simple operation, short recovery time, and low cost compared with other non-laser treatment (22). These benefits are the reasons why patients prefer PRP treatment. A previous study has also demonstrated that although the efficacy of CO2gas + PRP was worse than that of FCL + PRP, the complications of CO2gas + PRP were less compared with FCL + PRP, which led to significantly higher satisfaction of patients who received CO2gas + PRP (42).

There were some limitations to our study. On the one hand, the present study did not explore whether various treatments have varied therapeutic effects on patients of different genders, skin colors, and skin types. According to a report, women visit dermatologists for acne scars more frequently than men, and darker skin is more likely to cause complications (43). Furthermore, the effect of laser treatment varies on patients with different skin types. For instance, CO2 laser is more effective for rolling and boxcar scars than icepick scars. (boxcar scars are round or oval sunken scars that have relatively sharp edges with a diameter of 1.5 to 4 mm; rolling scars are wavy, greater than 4 mm in diameter, and have soft edges; icepick scars feature a V-shape, deep lesions, a diameter of less than 2 mm, and sharp edges) (4). However, the included studies did not classify patients by gender, skin color, and skin type. On the other hand, the follow-up duration in the included studies was relatively short. A study has reported an increase in the quantity and density of collagenous fiber in the dermal papilla for up to 8 weeks after laser treatment. Therefore, there may be a difference in the data obtained.

Conclusions

Combination therapy is recommended for acne scars. The combination of Er with PRP has the highest cure rate for acne scars, followed by FCL combined with 30%SC, or single FCL. FCL in combination with PRP improves acne scars most significantly, and 1064Nd combined with 15%VC is also effective. In contrast, patients prefer single treatment, with single FCL as the most satisfying option, followed by single PRP. This may be associated with their feelings about treatment, side effects, and costs. Therefore, Er + PRP and FCL + PRP can be used as the first choice for clinical treatment of acne scars. Additionally, using FCL alone is also an effective and elective treatment method due to its affordable cost and comfort.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA-NMA reporting checklist. Available at https://atm.amegroups.com/article/view/10.21037/atm-22-5997/rc

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-5997/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

  1. Dreno B, Gollnick HP, Kang S, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol 2015;29:3-11. [Crossref] [PubMed]
  2. Bazid H, Marae A, Tayel N, et al. Interleukin19 gene polymorphism and its serum level in acne vulgaris patients. J Immunoassay Immunochem 2022;43:1951291. [Crossref] [PubMed]
  3. Mohammed SMA, Sabry HH, Ameen SG, et al. MMP-1 (519 A/G) and TIMP-1 (372 T/C) genes polymorphism in an Egyptian sample of Acne vulgaris patients. J Cosmet Dermatol 2022;21:1705-11. [Crossref] [PubMed]
  4. Mahamoud WA, El Barbary RA, Ibrahim NF, et al. Fractional carbon dioxide laser combined with intradermal injection of autologous platelet-rich plasma versus noncross-linked hyaluronic acid in the treatment of atrophic postacne scars: A split face study. J Cosmet Dermatol 2020;19:1341-52. [Crossref] [PubMed]
  5. Taub AF. The Treatment of Acne Scars, a 30-Year Journey. Am J Clin Dermatol 2019;20:683-90. [Crossref] [PubMed]
  6. Zhang YJ, Chen YM, Shao XY, et al. Combination treatment with 30% salicylic acid and fractional CO(2) laser for acne scars: A 20-week prospective, randomized, split-face study. Dermatol Ther 2022;35:e15693. [Crossref] [PubMed]
  7. Samuels DV, Rosenthal R, Lin R, et al. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. J Am Acad Dermatol 2020;83:532-41. [Crossref] [PubMed]
  8. Shi Y, Jiang W, Li W, et al. Comparison of fractionated frequency-doubled 1,064/532 nm picosecond Nd:YAG lasers and non-ablative fractional 1,540 nm Er: glass in the treatment of facial atrophic scars: a randomized, split-face, double-blind trial. Ann Transl Med 2021;9:862. [Crossref] [PubMed]
  9. Lin L, Liao G, Chen J, et al. A systematic review and meta-analysis on the effects of the ultra-pulse CO2 fractional laser in the treatment of depressed acne scars. Ann Palliat Med 2022;11:743-55. [Crossref] [PubMed]
  10. Wang Y, Yu W, Zhang J, et al. Effect and Safety Analysis of PRP and Yifu Combined with Ultrapulsed CO(2) Lattice Laser in Patients with Sunken Acne Scar. J Healthc Eng 2022;2022:6803988. [Crossref] [PubMed]
  11. Sabry HH, Hegazy MS, Ahmed E, et al. Q-Switched 1064-nm Nd:YAG laser versus fractional carbon dioxide laser for post acne scarring: A split-face comparative study. Photodermatol Photoimmunol Photomed 2022;38:465-70. [Crossref] [PubMed]
  12. Lu K, Cai S. Efficacy and safety comparison between 1927 nm thulium laser and 2940 nm Er:YAG laser in the treatment of facial atrophic acne scarring: a prospective, simultaneous spilt-face clinical trial. Lasers Med Sci 2022;37:2025-31. [Crossref] [PubMed]
  13. Gawdat HI, El-Hadidy YA, Allam RSHM, et al. Autologous platelet-rich plasma ‘fluid’ versus ‘gel’ form in combination with fractional CO(2) laser in the treatment of atrophic acne scars: a split-face randomized clinical trial. J Dermatolog Treat 2022;33:2654-63. [Crossref] [PubMed]
  14. Emam AAM, Nada HA, Atwa MA, et al. Split-face comparative study of fractional Er:YAG laser versus microneedling radiofrequency in treatment of atrophic acne scars, using optical coherence tomography for assessment. J Cosmet Dermatol 2022;21:227-36. [Crossref] [PubMed]
  15. Allam N, Elshorbagy R. Monopolar radiofrequency versus pulsed dye laser for treatment of acne scars: a randomized clinical trial. Physiotherapy Quarterly 2022;30:73-7.
  16. Sirithanabadeekul P, Tantrapornpong P, Rattakul B, et al. Comparison of Fractional Picosecond 1064-nm Laser and Fractional Carbon Dioxide Laser for Treating Atrophic Acne Scars: A Randomized Split-Face Trial. Dermatol Surg 2021;47:e58-65. [Crossref] [PubMed]
  17. Rajput CD, Gore SB, Ansari MK, et al. A Prospective, Nonrandomized, Open-label Study, Comparing the Efficacy, Safety, and Tolerability of Fractional CO(2) Laser versus Fractional Microneedling Radio Frequency in Acne Scars. J Cutan Aesthet Surg 2021;14:177-83. [Crossref] [PubMed]
  18. Pratiwi I, Widayati RI. Muslimin. Effectiveness of the long-pulsed ND:YAG 1064 nm laser with 15% vitamin C (L-acid ascorbate) solution combination therapy in the treatment of patients with atrophic acne scars. Iran J Dermatol 2021;24:262-6.
  19. Lan T, Tang L, Xia A, et al. Comparison of Fractional Micro-Plasma Radiofrequency and Fractional Microneedle Radiofrequency for the Treatment of Atrophic Acne Scars: A Pilot Randomized Split-Face Clinical Study in China. Lasers Surg Med 2021;53:906-13. [Crossref] [PubMed]
  20. Kimwattananukul K, Noppakun N, Asawanonda P, et al. Topical 0.5% Timolol Maleate Significantly Enhances Skin-Barrier Restoration After Fractional Carbon Dioxide Laser Treatment for Acne Scars. Lasers Surg Med 2021;53:610-5. [Crossref] [PubMed]
  21. Feng H, Wu Y, Jiang M, et al. The Efficacy and Safety of Fractional 1064 nm Nd:YAG Picosecond Laser Combined With Intense Pulsed Light in the Treatment of Atrophic Acne Scar: A Split-Face Study. Lasers Surg Med 2021;53:1356-63. [Crossref] [PubMed]
  22. El-Hawary EE, Nassar S, Hodeib AA, et al. Ablative Fractional Carbon Dioxide Laser and Autologous Platelet-Rich Plasma in the Treatment of Atrophic Acne Scars: A Comparative Clinico-Immuno-Histopathological Study. Lasers Surg Med 2021;53:458-67. [Crossref] [PubMed]
  23. Cheng X, Yang Q, Su Y, et al. Comparison of 1565-nm Nonablative Fractional Laser and 10600-nm Ablative Fractional Laser in the Treatment of Mild to Moderate Atrophic Acne Scars. Dermatol Surg 2021;47:392-6. [Crossref] [PubMed]
  24. Chen L, Wang Y, Jiang L, et al. Comparison of 2940 nm Er: YAG laser treatment in the microlaser peel, fractional ablative laser, or combined modes for the treatment of concave acne scars. Medicine (Baltimore) 2021;100:e26642. [Crossref] [PubMed]
  25. Al-Dhalimi MA, Dahham Z. Split-face clinical comparative study of fractional Er:YAG (2940nm) laser versus long pulsed Nd:YAG (1064nm) laser in treatment of atrophic acne scar. J Cosmet Laser Ther 2021;23:35-40. [Crossref] [PubMed]
  26. Abdel-Maguid EM, Awad SM, Hassan YS, et al. Efficacy of stem cell-conditioned medium vs. platelet-rich plasma as an adjuvant to ablative fractional CO(2) laser resurfacing for atrophic post-acne scars: a split-face clinical trial. J Dermatolog Treat 2021;32:242-9. [Crossref] [PubMed]
  27. Sallam MAE, El Zawahry K, Ali Mustafa ARM. Split face comparative study of microneedling with platelet rich plasma versus Fractional carbon dioxide laser with platelet rich plasma in treatment of atrophic post acne scars. QJM 2021; [Crossref]
  28. Wen X, Li Y, Hamblin MR, et al. A randomized split-face, investigator-blinded study of a picosecond Alexandrite laser for post-inflammatory erythema and acne scars. Dermatol Ther 2020;33:e13941. [Crossref] [PubMed]
  29. Pooja T, Gopal KVT, Rao TN, et al. A Randomized Study to Evaluate the Efficacy Fractional CO(2)Laser, Microneedling and Platelet Rich Plasma in Post-Acne Scarring. Indian Dermatol Online J 2020;11:349-54. [Crossref] [PubMed]
  30. Lakkireddygari S. A comparitive study of fractional CO2 laser and combination of fractional CO2 laser with autologous platelet rich plasma in post acne scars. 24th World Congress of Dermatology Milan, 2019.
  31. Kwon HH, Yang SH, Lee J, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol 2020;100:adv00310. [Crossref] [PubMed]
  32. Kwon HH, Yang SH, Cho YJ, et al. Comparison of a 1064-nm neodymium-doped yttrium aluminum garnet picosecond laser using a diffractive optical element vs. a nonablative 1550-nm erbium-glass laser for the treatment of facial acne scarring in Asian patients: a 17-week prospective, randomized, split-face, controlled trial. J Eur Acad Dermatol Venereol 2020;34:2907-13. [Crossref] [PubMed]
  33. Abdel Kareem IM, Fouad MA, Ibrahim MK. Effectiveness of subcision using carboxytherapy plus fractional carbon dioxide laser resurfacing in the treatment of atrophic acne scars: comparative split face study. J Dermatolog Treat 2020;31:296-9. [Crossref] [PubMed]
  34. Kaçar N, Dursun R, Akbay M, et al. The early and late efficacy of single-pass fractional carbondioxide laser, fractional radiofrequency, and their combination in acne scars: A prospective, split-face, single-blinded, controlled clinical study. Dermatol Ther 2020;33:e14444. [Crossref] [PubMed]
  35. Chopra A. Comparative study of microneedling vs fractional CO2 in management of post acne scars. 24th World Congress of Dermatology Milan, 2019.
  36. Chen CJ. Treatment of acne vulgaris with intense pulsed light and pulsed dye laser: a split face, randomized controlled trial. 24th World Congress of Dermatology Milan, 2019.
  37. Chayavichitsilp P, Limtong P, Triyangkulsri K, et al. Comparison of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser and fractional 1550-nm erbium fiber laser in facial acne scar treatment. Lasers Med Sci 2020;35:695-700. [Crossref] [PubMed]
  38. Arsiwala NZ, Inamadar AC, Adya KA. A Comparative Study to Assess the Efficacy of Fractional Carbon Dioxide Laser and Combination of Fractional Carbon Dioxide Laser with Topical Autologous Platelet-rich Plasma in Post-acne Atrophic Scars. J Cutan Aesthet Surg 2020;13:11-7. [Crossref] [PubMed]
  39. An MK, Hong EH, Suh SB, et al. Combination Therapy of Microneedle Fractional Radiofrequency and Topical Poly-Lactic Acid for Acne Scars: A Randomized Controlled Split-Face Study. Dermatol Surg 2020;46:796-802. [Crossref] [PubMed]
  40. Al-Sultany HA. A comparative study of the efficacy of fractional co2 laser versus micro needling fractional radiofrequency in the management of atrophic acne scars among Iraqi patients. Ann Tropical Med Public Health 2020;23:18.
  41. El-Taieb MA, Ibrahim HM, Hegazy EM, et al. Fractional Erbium-YAG Laser and Platelet-Rich Plasma as Single or Combined Treatment for Atrophic Acne Scars: A Randomized Clinical Trial. Dermatol Ther (Heidelb) 2019;9:707-17. [Crossref] [PubMed]
  42. Al Taweel AI, Al Refae AA, Hamed AM, et al. Comparative study of the efficacy of Platelet-rich plasma combined with carboxytherapy vs its use with fractional carbon dioxide laser in atrophic acne scars. J Cosmet Dermatol 2019;18:150-5. [Crossref] [PubMed]
  43. Abou Eitta RS, Ismail AA, Abdelmaksoud RA, et al. Evaluation of autologous adipose-derived stem cells vs. fractional carbon dioxide laser in the treatment of post acne scars: a split-face study. Int J Dermatol 2019;58:1212-22. [Crossref] [PubMed]
  44. Elsaie ML, Ibrahim SM, Saudi W. Ablative Fractional 10 600 nm Carbon Dioxide Laser Versus Non-ablative Fractional 1540 nm Erbium-Glass Laser in Egyptian Post-acne Scar patients. J Lasers Med Sci 2018;9:32-5. [Crossref] [PubMed]
  45. Dierickx C. Using normal and high pulse coverage with picosecond laser treatment of wrinkles and acne scarring: Long term clinical observations. Lasers Surg Med 2018;50:51-5. [Crossref] [PubMed]
  46. Abdel Aal AM, Ibrahim IM, Sami NA, et al. Evaluation of autologous platelet-rich plasma plus ablative carbon dioxide fractional laser in the treatment of acne scars. J Cosmet Laser Ther 2018;20:106-13. [Crossref] [PubMed]
  47. Saluja SS, Walker ML, Summers EM, et al. Safety of non-ablative fractional laser for acne scars within 1 month after treatment with oral isotretinoin: A randomized split-face controlled trial. Lasers Surg Med 2017;49:886-90. [Crossref] [PubMed]
  48. Osman MA, Shokeir HA, Fawzy MM. Fractional Erbium-Doped Yttrium Aluminum Garnet Laser Versus Microneedling in Treatment of Atrophic Acne Scars: A Randomized Split-Face Clinical Study. Dermatol Surg 2017;43:S47-56. [Crossref] [PubMed]
  49. Min S, Park SY, Moon J, et al. Comparison between Er:YAG laser and bipolar radiofrequency combined with infrared diode laser for the treatment of acne scars: Differential expression of fibrogenetic biomolecules may be associated with differences in efficacy between ablative and non-ablative laser treatment. Lasers Surg Med 2017;49:341-7. [Crossref] [PubMed]
  50. Kwon HH, Park HY, Choi SC, et al. Combined Fractional Treatment of Acne Scars Involving Non-ablative 1,550-nm Erbium-glass Laser and Micro-needling Radiofrequency: A 16-week Prospective, Randomized Split-face Study. Acta Derm Venereol 2017;97:947-51. [Crossref] [PubMed]
  51. Khamthara J, Kumtornrut C, Pongpairoj K, et al. Silicone gel enhances the efficacy of Er:YAG laser treatment for atrophic acne scars: A randomized, split-face, evaluator-blinded, placebo-controlled, comparative trial. J Cosmet Laser Ther 2018;20:96-101. [Crossref] [PubMed]
  52. Faghihi G, Keyvan S, Asilian A, et al. Efficacy of autologous platelet-rich plasma combined with fractional ablative carbon dioxide resurfacing laser in treatment of facial atrophic acne scars: A split-face randomized clinical trial. Indian J Dermatol Venereol Leprol 2016;82:162-8. [Crossref] [PubMed]
  53. Cachafeiro T, Escobar G, Maldonado G, et al. Comparison of Nonablative Fractional Erbium Laser 1,340 nm and Microneedling for the Treatment of Atrophic Acne Scars: A Randomized Clinical Trial. Dermatol Surg 2016;42:232-41. [Crossref] [PubMed]
  54. Anupama YG, Wahab AJ. Effectiveness of CO(2) laser with subcision in patients with acne scars. J Cosmet Laser Ther 2016;18:367-71. [Crossref] [PubMed]
  55. Faghihi G, Nouraei S, Asilian A, et al. Efficacy of Punch Elevation Combined with Fractional Carbon Dioxide Laser Resurfacing in Facial Atrophic Acne Scarring: A Randomized Split-face Clinical Study. Indian J Dermatol 2015;60:473-8. [Crossref] [PubMed]
  56. Chae WS, Seong JY, Jung HN, et al. Comparative study on efficacy and safety of 1550 nm Er:Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. J Cosmet Dermatol 2015;14:100-6. [Crossref] [PubMed]
  57. Yuan XH, Zhong SX, Li SS. Comparison study of fractional carbon dioxide laser resurfacing using different fluences and densities for acne scars in Asians: a randomized split-face trial. Dermatol Surg 2014;40:545-52. [Crossref] [PubMed]
  58. Rongsaard N, Rummaneethorn P. Comparison of a fractional bipolar radiofrequency device and a fractional erbium-doped glass 1,550-nm device for the treatment of atrophic acne scars: a randomized split-face clinical study. Dermatol Surg 2014;40:14-21. [Crossref] [PubMed]
  59. Leheta TM, Abdel Hay RM, Hegazy RA, et al. Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. J Dermatolog Treat 2014;25:137-41. [Crossref] [PubMed]
  60. Ahmed R, Mohammed G, Ismail N, et al. Randomized clinical trial of CO2 LASER pinpoint irradiation technique versus chemical reconstruction of skin scars (CROSS) in treating ice pick acne scars. J Cosmet Laser Ther 2014;16:8-13. [Crossref] [PubMed]
  61. Zhang Z, Fei Y, Chen X, et al. Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split-face clinical study. Dermatol Surg 2013;39:559-66. [Crossref] [PubMed]
  62. Mohammed G. Randomized clinical trial of CO2 laser pinpoint irradiation technique with/without needling for ice pick acne scars. J Cosmet Laser Ther 2013;15:177-82. [Crossref] [PubMed]
  63. Manuskiatti W, Iamphonrat T, Wanitphakdeedecha R, et al. Comparison of fractional erbium-doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatol Surg 2013;39:111-20. [Crossref] [PubMed]
  64. Lee JW, Kim BJ, Kim MN, et al. The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split-face trial. Dermatol Surg 2011;37:931-8. [Crossref] [PubMed]
  65. Asilian A, Salimi E, Faghihi G, et al. Comparison of Q-Switched 1064-nm Nd:YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. J Res Med Sci 2011;16:1189-95.
  66. Alexis A, Coley M, Alam M, et al. editors. A prospective randomized split-face comparison study of non-ablative fractional laser resurfacing in the treatment of acne scarring in fitzpatrick skin phototypes IV-VI. Lasers in Surgery and Medicine; MALDEN 02148, MA USA: Wiley-Blackwell Commerce Place; 2011;43:939.
  67. Mahmoud BH, Srivastava D, Janiga JJ, et al. Safety and efficacy of erbium‐doped yttrium aluminum garnet fractionated laser for treatment of acne scars in type IV to VI skin. Dermatol Surg 2010;36:602-9. [Crossref] [PubMed]
  68. Hedelund L, Moreau KE, Beyer DM, et al. Fractional nonablative 1,540-nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers Med Sci 2010;25:749-54. [Crossref] [PubMed]
  69. Cho SB, Lee SJ, Cho S, et al. Non-ablative 1550-nm erbium-glass and ablative 10 600-nm carbon dioxide fractional lasers for acne scars: a randomized split-face study with blinded response evaluation. J Eur Acad Dermatol Venereol 2010;24:921-5. [Crossref] [PubMed]
  70. Wanitphakdeedecha R, Manuskiatti W, Siriphukpong S, et al. Treatment of punched-out atrophic and rolling acne scars in skin phototypes III, IV, and V with variable square pulse erbium:yttrium-aluminum-garnet laser resurfacing. Dermatol Surg 2009;35:1376-83. [Crossref] [PubMed]
  71. Min SU, Choi YS, Lee DH, et al. Comparison of a long-pulse Nd:YAG laser and a combined 585/1,064-nm laser for the treatment of acne scars: a randomized split-face clinical study. Dermatol Surg 2009;35:1720-7. [Crossref] [PubMed]
  72. Lee DH, Choi YS, Min SU, et al. Comparison of a 585-nm pulsed dye laser and a 1064-nm Nd:YAG laser for the treatment of acne scars: A randomized split-face clinical study. J Am Acad Dermatol 2009;60:801-7. [Crossref] [PubMed]
  73. Kim HJ, Kim TG, Kwon YS, et al. Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split-face trial. Lasers Surg Med 2009;41:545-9. [Crossref] [PubMed]
  74. Yaghmai D, Garden JM, Bakus AD, et al. Comparison of a 1,064 nm laser and a 1,320 nm laser for the nonablative treatment of acne scars. Dermatol Surg 2005;31:903-9. [Crossref] [PubMed]
  75. Tanzi EL, Alster TS. Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatol Surg 2004;30:152-7. [Crossref] [PubMed]
  76. Lee SJ, Kang JM, Chung WS, et al. Ablative non-fractional lasers for atrophic facial acne scars: a new modality of erbium:YAG laser resurfacing in Asians. Lasers Med Sci 2014;29:615-9. [Crossref] [PubMed]
  77. Husein-ElAhmed H, Steinhoff M. Comparative appraisal with meta-analysis of erbium vs. CO(2) lasers for atrophic acne scars. J Dtsch Dermatol Ges 2021;19:1559-68. [Crossref] [PubMed]
  78. Chang HC, Sung CW, Lin MH. Efficacy of Autologous Platelet-Rich Plasma Combined With Ablative Fractional Carbon Dioxide Laser for Acne Scars: A Systematic Review and Meta-Analysis. Aesthet Surg J 2019;39:NP279-87. [Crossref] [PubMed]
Cite this article as: Zhao Z, Wang T, Li W, Liang Q, Chen W. To evaluate the efficacy and safety of laser interventions for facial acne scars: a systematic review and Bayesian network meta-analysis. Ann Transl Med 2022;10(24):1396. doi: 10.21037/atm-22-5997

Article Options

Download Citation

Share